In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3834-3844

  Dezzutti, Charlene S ^a,b   James, V Nicole ^a   Ramos, Artur ^a   Sullivan, Sharon T ^a   Siddig, Aladin ^a   Bush, Timothy J ^a   Grohskopf, Lisa A ^a   Paxton, Lynn ^a   Subbarao, Shambavi ^a   Hart, Clyde E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARRAGEENAN; CELLACEFATE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PLACEBO; PRO 2000; TOPICAL MICROBICIDE; UNCLASSIFIED DRUG; VENA GEL; VIVAGEL;

ARTICLE; BLOOD; CELL LINE; CELL MEMBRANE RESISTANCE; CLINICAL TRIAL; COLON MUCOSA; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; RECTUM MUCOSA; UTERINE CERVIX EPITHELIUM; VIRUS TRANSMISSION;

ANTI-INFECTIVE AGENTS, LOCAL; CACO-2 CELLS; COLON; EPITHELIAL CELLS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MONOCYTES; RECTUM; UROGENITAL SYSTEM;

EID: 4644225675     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3834-3844.2004     Document Type: Article

References (61)

1. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, W. A. Harrison, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
2. Balzarini, J., L. Naesens, E. Verbeken, M. Laga, L. Van Damme, M. Parniak, L. Van Mellaert, J. Anne, and E. De Clercq. 1998. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12:1129-1138.
3. Bernstein, D. I., L. R. Stanberry, S. Sacks, N. K. Ayisi, Y. H. Gong, J. Ireland, R. J. Mumper, G. Holan, B. Matthews, T. McCarthy, and N. Bourne. 2003. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 47:3784-3788.
4. Borkow, G., H. Salomon, M. A. Wainberg, and M. A. Parniak. 2002. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res. Hum. Retrovir. 18:711-714.
5. Bourinbaiar, A. S., and E. C. Fruhstorfer. 1996. The efficacy of nonoxynol-9 from an in vitro point of view. AIDS 10:558-559.
6. Bourne, N., L. R. Stanberry, E. R. Kern, G. Holan, B. Matthews, and D. I. Bernstein. 2000. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44:2471-2474.
7. Buckheit, R. W., Jr., M. Hollingshead, S. Stinson, V. Fliakas-Boltz, L. A. Pallansch, J. Roberson, W. Decker, C. Elder, S. Borgel, C. Bonomi, R. Shores, T. Siford, L. Malspeis, and J. P. Bader. 1997. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res. Hum. Retrovir. 13:789-796.
8. Centers for Disease Control and Prevention. 11 August 2000, posting date. Letter dated 4 August 2000 from the Director, National Center for HIV, STD, and TB Prevention. [Online.] http://www.cdc.gov/hiv/pubs/mmwr /mmwr11aug00.htm.
9. Centers for Disease Control and Prevention. 1993. Update: barrier protection against HIV infection and other sexually transmitted diseases. Morb. Mortal. Wkly. Rep. 42:589-597.
10. Chesson, H. W., and S. D. Pinkerton. 2000. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J. Acquir. Immune Defic. Syndr. 24:48-56.
11. Coggins, C., K. Blanchard, F. Alvarez, V. Brache, E. Weisberg, P. H. Kilmarx, M. Lacarra, R. Massai, D. Mishell, Jr., A. Salvatierra, P. Witwatwongwana, C. Elias, and C. Ellertson. 2000. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76:480-483.
12. Cummins, J. E., Jr., and C. S. Dezzutti. 2000. Sexual HIV-1 transmission and mucosal defense mechanisms. AIDS Rev. 2:144-154.
13. Daher, K. A., M. E. Selsted, and R. I. Lehrer. 1986. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60:1068-1074.
14. Dezzutti, C. S., P. C. Guenthner, J. E. Cummins, Jr., T. Cabrera, J. H. Marshall, A. Dillberger, and R. B. Lal. 2001. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 183:1204-1213.
15. Elias, C. J., C. Coggins, F. Alvarez, V. Brache, I. S. Fraser, M. Lacarra, P. Lahteenmaki, R. Massai, D. R. Mishell, Jr., D. M. Phillips, and A. M. Salvatierra. 1997. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 56:387-389.
16. Elias, C. J., and C. Coggins. 1996. Female-controlled methods to prevent sexual transmission of HIV. AIDS 10(Suppl. 3):S43-S51.
17. Federal Register. 2001. Opportunity to collaborate in the evaluation of topical microbicides to reduce heterosexual transmission of human immunodeficiency virus (HIV). Fed. Regist. 66:34453.
18. Federal Register. 2002. Opportunity to collaborate in the evaluation of topical microbicides to reduce sexual transmission of human immunodeficiency virus (HIV). Fed. Regist. 67:35114.
19. Federal Register. 2001. Opportunity to collaborate in the evaluation of topical microbicides to reduce transmission of human immunodeficiency virus (HIV) among men who have sex with men (MSM). Fed. Regist. 66: 34452.
20. Fleming, D. T., and J. N. Wasserheit. 1999. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 75:3-17.
21. Fogh, J., W. C. Wright, and J. D. Loveless. 1977. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214.
22. Gyotoku, T., L. Aurelian, and A. R. Neurath. 1999. Cellulose acetate phthalate (CAP): an "inactive" pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 10:327-332.
23. Hladik, F., G. Lentz, R. E. Akridge, G. Peterson, H. Kelley, A. McElroy, and M. J. McElrath. 1999. Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract. J. Virol. 73:5833-5842.
24. Jennings, R., and A. Clegg. 1993. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in vitro. J. Antimicrob. Chemother. 32: 71-82.
25. Khanna, K. V., K. J. Whaley, L. Zeitlin, T. R. Moench, K. Mehrazar, R. A. Cone, Z. Liao, J. E. Hildreth, T. E. Hoen, L. Shultz, and R. B. Markham. 2002. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Investig. 109:205-211.
26. Kuramoto, H. 1972. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet. Gynaecol. Jpn. 19:47-58.
27. Leibovitz, A., J. C. Stinson, W. B. McCombs III, C. E. McCoy, K. C. Mazur, and N. D. Mabry. 1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36:4562-4569.
28. Lushbaugh, W. B., A. C. Blossom, P. H. Shah, A. K. Banga, J. M. Jaynes, J. D. Cleary, and R. W. Finley. 2000. Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in Lactobacillus- pretreated, estrogenized young mice. Am. J. Trop. Med. Hyg. 63:284-289.
29. Mackewicz, C. E., J. Yuan, P. Tran, L. Diaz, E. Mack, M. E. Selsted, and J. A. Levy. 2003. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17:F23-F32.
30. Maguire, R. A., N. Bergman, and D. M. Phillips. 2001. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex. Transm. Dis. 28:259-265.
31. Malkovsky, M., A. Newell, and A. G. Dalgleish. 1988. Inactivation of HIV by nonoxynol-9. Lancet 1:645.
32. Manson, K. H., M. S. Wyand, C. Miller, and A. R. Neurath. 2000. Effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob. Agents Chemother. 44:3199-3202.
33. Mayer, K. H., S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg for the HIV Prevention Trials Network (HPTN) 020 Protocol Team. 2003. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17:321-329.
34. Mohan, P., R. Singh, and M. Baba. 1991. Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2. J. Med. Chem. 34:212-217.
35. Neurath, A. R., Y. Y. Li, R. Mandeville, and L. Richard. 2000. In vitro activity of a cellulose acetate phthalate topical cream against organisms associated with bacterial vaginosis. J. Antimicrob. Chemother. 45:713-714.
36. Neurath, A. R., N. Strick, S. Jiang, Y. Y. Li, and A. K. Debnath. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2:6.
37. Neurath, A. R., N. Strick, and Y. Y. Li. 2002. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis. 2:27.
38. Neurath, A. R., N. Strick, Y. Y. Li, and A. K. Debnath. 2001. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1:17.
39. Neurath, A. R., N. Strick, Y. Y. Li, K. Lin, and S. Jiang. 1999. Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals 27:11-21.
40. Patton, D. L., Y. T. Cosgrove Sweeney, L. K. Rabe, and S. L. Hillier. 2002. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex. Transm. Dis. 29:581-587.
41. Patton, D. L., G. G. Kidder, Y. C. Sweeney, L. K. Rabe, A. M. Clark, and S. L. Hillier. 1996. Effects of nonoxynol-9 on vaginal microflora and chlamydial infection in a monkey model. Sex. Transm. Dis. 23:461-464.
42. Phillips, D. M., C. L. Taylor, V. R. Zacharopoulos, and R. A. Maguire. 2000. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 62:149-154.
43. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
44. Roddy, R. E., S. Chutivongse, and S. Niruthisard. 1992. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Lancet 339: 1371-1375.
45. Rusconi, S., M. Moonis, D. P. Merrill, P. V. Pallai, E. A. Neidhardt, S. K. Singh, K. J. Willis, M. S. Osburne, A. T. Profy, J. C. Jenson, and M. S. Hirsch. 1996. Naphthalene sulfonate polymers with CD4-blocking and antihuman immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40:234-236.
46. Stafford, M. K., H. Ward, A. Flanagan, I. J. Rosenstein, D. Taylor-Robinson, J. R. Smith, J. Weber, and V. S. Kitchen. 1998. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:327-331.
47. Stein, Z. A. 1990. HIV prevention: the need for methods women can use. Am. J. Public Health 80:460-462.
48. Sullivan, P. S., A. N. Do, D. Ellenberger, C. P. Pau, S. Paul, K. Robbins, M. Kalish, C. Storck, C. A. Schable, H. Wise, C. Tetteh, J. L. Jones, J. McFarland, C. Yang, R. B. Lal, and J. W. Ward. 2000. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States. J. Infect. Dis. 181: 463-469.
49. Sykes, J. A., J. Whitescarver, P. Jernstrom, J. F. Nolan, and P. Byatt. 1970. Some properties of a new epithelial cell line of human origin. J. Natl. Cancer Inst. 45:107-122.
50. Taha, T. E., D. R. Hoover, G. A. Dallabetta, N. I. Kumwenda, L. A. Mtimavalye, L. P. Yang, G. N. Liomba, R. L. Broadhead, J. D. Chiphangwi, and P. G. Miotti. 1998. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12:1699-1706.
51. UNAIDS. 2002. AIDS epidemic update: December 2002. [Online.] http: //www.unaids.org.
52. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, S. S. Karim, B. Masse, J. Perriens, M. Laga, and COL-1492 Study Group. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
53. Van Damme, L., A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. 2000. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76: 126-130.
54. Velleca, W. M., D. F. Palmer, P. M. Feorino, D. T. Warfield, J. W. Krebs, B. Forrester, S. Phillips, and C. Y. Ou. 1991. Isolation, culture, and identification of human immunodeficiency virus: procedural guide. U.S. Department of Health and Human Services, Washington, D.C.
55. Vittinghoff, E., J. Douglas, F. Judson, D. McKirnan, K. MacQueen, and S. P. Buchbinder. 1999. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am. J. Epidemiol. 150: 306-311.
56. Wahl, S. M., T. Greenwell-Wild, G. Peng, H. Hale-Donze, T. M. Doherty, D. Mizel, and J. M. Orenstein. 1998. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc. Natl. Acad. Sci. USA 95:12574-12579.
57. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
58. Witvrouw, M., V. Fikkert, W. Pluymers, B. Matthews, K. Mardel, D. Schols, J. Raff, Z. Debyser, E. De Clercq, G. Holan, and C. Pannecouque. 2000. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 58:1100-1108.
59. Zacharopoulos, V. R., and D. M. Phillips. 1997. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin. Diagn. Lab. Immunol. 4:465-468.
60. Zeitlin, L., T. E. Hoen, S. L. Achilles, T. A. Hegarty, A. E. Jerse, J. W. Kreider, S. S. Olmsted, K. J. Whaley, R. A. Cone, and T. R. Moench. 2001. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex. Transm. Dis. 28:417-423.
61. Zhang, H., G. Dornadula, M. Beumont, L. Livornese, Jr., B. Van Uitert, K. Henning, and R. J. Pomerantz. 1998. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339:1803-1809.